Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated July 18, 2025, provides an update regarding the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) review of Blenrep (belantamab mafodotin-blmf). The filing addresses the treatment of relapsed or refractory multiple myeloma.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a regulatory update focused on clinical trial outcomes and regulatory status rather than financial performance.
Material Changes and Regulatory Status
- ODAC Vote: The FDA ODAC voted against the overall benefit/risk profile of Blenrep combinations at the proposed dosage for adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.
- Upcoming Decision: The FDA will consider the committee's recommendation before the Prescription Drug User Fee Act (PDUFA) decision date of July 23, 2025.
- Global Approvals: Blenrep combinations are already approved in the UK (April 2025) and Japan (May 2025).
- Pending Reviews: Applications are under review in the European Union and China (with Breakthrough Therapy Designation and priority review).
Outlook, Management Commentary, and Clinical Data
Management Commentary: GSK states it remains confident in the benefit/risk profile of Blenrep and will continue to work closely with the FDA. The company highlights the high unmet need for novel treatments that extend survival in this patient population.
Clinical Trial Results:
- DREAMM-7 (Blenrep + Bortezomib + Dexamethasone vs. Daratumumab + Bortezomib + Dexamethasone):
- Median Progression-Free Survival (PFS): 36.6 months vs. 13.4 months (HR 0.41).
- Overall Survival (OS): 42% reduction in risk of death (HR 0.58); 3-year OS rate was 74% vs. 60%.
- DREAMM-8 (Blenrep + Pomalidomide + Dexamethasone vs. Bortezomib + Pomalidomide + Dexamethasone):
- Median PFS: 32.6 months vs. 12.5 months (HR 0.49).
- At one year, 71% of patients in the Blenrep arm were alive and progression-free compared to 51% in the control arm.
- OS trend was positive but not statistically significant at interim analysis (HR 0.77).
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ due to risks described in GSK's 2024 Form 20-F and Q1 2025 results.
Key Facts for Investor Verification
- Verify the final FDA decision on Blenrep expected on July 23, 2025, following the negative ODAC vote.
- Monitor the status of regulatory applications in the EU and China, which are currently under review.
- Assess the potential impact of the US regulatory outcome on GSK's oncology pipeline and revenue projections for multiple myeloma treatments.
- Review the safety profile and dosage adjustments that may be required to address the ODAC's concerns regarding the benefit/risk profile.